Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jan 8;13(1):134.
doi: 10.3390/biomedicines13010134.

A Narrative Review of Prognostic Gene Signatures in Oral Squamous Cell Carcinoma Using LASSO Cox Regression

Nur Fatinazwa Mohd Faizal  1 , Saptarsi Shai  2 , Bansi P Savaliya  3 , Lee Peng Karen-Ng  1 , Rupa Kumari  4 , Rahul Kumar  4 , Vui King Vincent-Chong  5
Affiliations
Review

A Narrative Review of Prognostic Gene Signatures in Oral Squamous Cell Carcinoma Using LASSO Cox Regression

Nur Fatinazwa Mohd Faizal et al. Biomedicines. .

Abstract

Oral squamous cell carcinoma (OSCC) is one of the most common malignancies of the head and neck squamous cell carcinoma (HNSCC). HNSCC is recognized as the eighth most commonly occurring cancer globally in men. It is essential to distinguish between cancers arising in the head and neck regions due to significant differences in their etiologies, treatment approaches, and prognoses. As the Cancer Genome Atlas (TCGA) dataset is available in HNSCC, the survival analysis prognosis of OSCC patients based on the TCGA dataset for discovering gene expression-based prognostic biomarkers is limited. To address this paucity, we aimed to provide comprehensive evidence by recruiting studies that have reported new biomarkers/signatures to establish a prognostic model to predict the survival of OSCC patients. Using PubMed search, we have identified 34 studies that have been using the least absolute shrinkage and selection operator (LASSO)-based Cox regression analyses to establish signature prognosis that related to different pathways in OSCC from the past 4 years. Our review was focused on summarizing these signatures and implications for targeted therapy using FDA-approved drugs. Furthermore, we conducted an analysis of the LASSO Cox regression gene signatures. Our findings revealed 13 studies that correlated a greater number of regulatory T cells (Tregs) cells in protective gene signatures with increased recurrence-free and overall survival rates. Conversely, two studies displayed an opposing trend in cases of OSCC. We will also explore how the dysregulation of these signatures impacts immune status, promoting tumor immune evasion or, conversely, enhancing immune surveillance. Overall, this review will provide new insight for future anti-cancer therapies based on the potential gene that is associated with poor prognosis in OSCC.

Keywords: HNSCC; LASSO; OSCC; chemotherapy; gene signature; immunotherapy; prognosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Similar articles

See all similar articles

Cited by

References

    1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Barsouk A., Aluru J.S., Rawla P., Saginala K., Barsouk A. Epidemiology, Risk Factors, and Prevention of Head and Neck Squamous Cell Carcinoma. Med. Sci. 2023;11:42. doi: 10.3390/medsci11020042. - DOI - PMC - PubMed
    1. Caudell J.J., Gillison M.L., Maghami E., Spencer S., Pfister D.G., Adkins D., Birkeland A.C., Brizel D.M., Busse P.M., Cmelak A.J. NCCN Guidelines® insights: Head and neck cancers, version 1.2022: Featured updates to the NCCN guidelines. J. Natl. Compr. Cancer Netw. 2022;20:224–234. doi: 10.6004/jnccn.2022.0016. - DOI - PubMed
    1. Sindhu S.K., Bauman J.E. Current Concepts in Chemotherapy for Head and Neck Cancer. Oral Maxillofac. Surg. Clin. N. Am. 2019;31:145–154. doi: 10.1016/j.coms.2018.09.003. - DOI - PMC - PubMed
    1. Chung C.H., Li J., Steuer C.E., Bhateja P., Johnson M., Masannat J., Poole M.I., Song F., Hernandez-Prera J.C., Molina H., et al. Phase II Multi-institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. Clin. Cancer Res. 2022;28:2329–2338. doi: 10.1158/1078-0432.CCR-21-3849. - DOI - PMC - PubMed

LinkOut - more resources